Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

about

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

Item

http://www.wikidata.org/entity/Q57492451

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Initial Report of a Phase I St ...... ractory Acute Myeloid Leukemia

@en

Initial Report of a Phase I St ...... ractory Acute Myeloid Leukemia

@nl

type

Item

label

Initial Report of a Phase I St ...... ractory Acute Myeloid Leukemia

@en

Initial Report of a Phase I St ...... ractory Acute Myeloid Leukemia

@nl

prefLabel

Initial Report of a Phase I St ...... ractory Acute Myeloid Leukemia

@en

Initial Report of a Phase I St ...... ractory Acute Myeloid Leukemia

@nl

P1476

Initial Report of a Phase I St ...... ractory Acute Myeloid Leukemia

@en

P2093

Ami Patel

http://www.w3.org/2001/XMLSchema#string

Antonio Cavazos

http://www.w3.org/2001/XMLSchema#string

April Deshmukh

http://www.w3.org/2001/XMLSchema#string

Jan Burger

http://www.w3.org/2001/XMLSchema#string

Kiran Naqvi

http://www.w3.org/2001/XMLSchema#string

Lina Han

http://www.w3.org/2001/XMLSchema#string

Mythili Koneru

http://www.w3.org/2001/XMLSchema#string

Prajwal Boddu

http://www.w3.org/2001/XMLSchema#string

Prithviraj Bose

http://www.w3.org/2001/XMLSchema#string

Xuelin Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Involvement of chemokine receptors in breast cancer metastasis

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion

FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation.

Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial.

Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group.

Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers.

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.

Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist

Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis.

Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience

P304

369

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FONC.2018.00369

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30319961

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

cancer research

P932

6167965

http://www.w3.org/2001/XMLSchema#string